Truist lowered the firm’s price target on Inspire Medical (INSP) to $235 from $250 and keeps a Buy rating on the shares. The company’s Q4 results saw a “solid” earnings and gross margin beat, though its profit upside may get overshadowed by a DOJ civil investigative demand, the analyst tells investors in a research note. This could weigh on shares temporarily, but given Inspire’s inflecting profitability and positive cash position, it should be manageable for the stock, Truist added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $248 from $252 at Baird
- Inspire Medical price target lowered to $220 from $230 at Morgan Stanley
- Inspire Medical price target lowered to $195 from $198 at Wells Fargo
- Inspire Medical Systems: Balancing Strong Performance with Operational Challenges and Regulatory Risks
- Inspire Medical Systems: Strong Buy Rating Amid Growth Prospects and DOJ Investigation Challenges